Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET

This publication has 44 references indexed in Scilit:

• Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability
  Clinical Cancer Research, 2010
• [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy
  Journal of Clinical Oncology, 2009
• FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
  British Journal of Cancer, 2009
• Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition
  Molecular Cancer Therapeutics, 2009
• Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
  Cancer Research, 2008
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
  The Lancet, 2008
• Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma
  Clinical Cancer Research, 2008
• Targeting angiogenesis with oral agents
  Annals of Oncology, 2006
• In‐vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO
  NMR in Biomedicine, 2002
• Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
  European Journal of Nuclear Medicine and Molecular Imaging, 1996